This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gibson, C. M. Search for Related Content PubMed PubMed Citation Articles by Gibson, C. M.

Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial

C. Michael Gibson, MS, MD, FACC, Mukesh Goel, MD, David J. Cohen, MD, MSc, Robert N. Piana, MD, FACC, Lawrence I. Deckelbaum, MD, FACC^||, Katherine E. Harris, DrPH^||, Spencer B. King, III, MD, FACC^¶ for the RESTORE Investigators^#

Veterans Affairs Medical Center, West Roxbury, Massachusetts, USA
Cardiovascular Division, Beth Israel-Deaconess Medical Center, Boston, Massachusetts, USA
Cardiac Catheterization Laboratory, Brigham and Women’s Hospital, Boston, Massachusetts, USA
^|| Merck Research Laboratories, Blue Bell, Pennsylvania, USA
^¶ Emory University Hospital, Atlanta, Georgia, USA

View larger version (28K): [in a new window]   Figure 1 Cumulative distribution functions of minimal lumen diameters before and after intervention and at 6 months of follow-up for tirofiban- and placebo-treated patients. As can be seen, the cumulative distribution functions do not differ significantly between the treatment groups and are nearly superimposible at all time points.

View larger version (17K): [in a new window]   Figure 2 Kaplan-Meier curves of clinical outcomes at multiple time points. The 3% absolute reduction in this composite end point that was observed within 48 h of initial treatment persisted over the 6-month follow-up period, but there was no evidence of additional late clinical benefit. At 6 months, the composite end point occurred in 1,069 placebo-treated patients (27.1%) and in 1,070 tirofiban-treated patients (24.1%, p = 0.11).